SCHEMBL9607742

SCHEMBL9607742

Cc1ccc(-c2ncnc(NC3CCc4nc(N)sc4C3)c2O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 4/20 0.43
DRD2 P14416 3/20 0.43
HRH2 P25021 2/20 0.43
ADRA2A P08913 2/20 0.43
DRD4 P21917 2/20 0.43
ADRB2 P07550 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
HTR1B P28222 1/20 0.43
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43
ADRA1A P35348 1/20 0.43
HRH1 P35367 1/20 0.43
HTR2B P41595 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
SCN3A Q9NY46 4/20 0.42
SCN4A P35499 3/20 0.42
SCN9A Q15858 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6920488 0.87 DRD3 (0.42) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL9607746 0.83 LMNA (0.42) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL6918151 0.79 DRD3 (0.37) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL6920001 0.74 LMNA (0.41) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL1231164 0.72 F9 (0.47) MAPK1F9F11F7CYP2C9
SCHEMBL9607740 0.71 F9 (0.53) F9F11F7CYP2C9F10
SCHEMBL23654132 0.70 SCN3A (0.64) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL16082217 0.70 SCN9A (0.44) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL16082209 0.70 DRD3 (0.42) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL16082785 0.70 IRAK4 (0.47) DRD3DRD2HRH2ADRA2ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 DRD3 4354/4885DRD2 4639/4885HRH2 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.